AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
TranzFect technology enters phase I clinical trials.(Brief Article)
1902 MAR 27 - (NewsRx.com & NewsRx.net) -- CytRx Corp. (CYTR) announced that its TranzFect technology is incorporated in an experimental DNA-based HIV vaccine being developed by Merck & Co., Inc., (MRK) that has now entered phase I clinical trials.
Merck scientists hope the clinical trials will lead to the development of an HIV vaccine that can effectively prevent, or attenuate, the development of AIDS resulting from HIV infection, as well as help treat HIV infection in infected patients taking antiretroviral therapy. The objectives of the phase I studies are to evaluate the vaccine's safety, tolerability and immunogenicity, which is the ability to stimulate an effective anti-HIV immune response.
TranzFect is a proprietary technology developed by CytRx that may contribute to the overall effectiveness of DNA-based vaccines in two important ways. It may enhance delivery of DNA to target effector cells within the immune system. In addition, TranzFect may act as an adjuvant to increase the ...
- TranzFect technology enters phase I clinical trials.(Brief Article)
- Newspaper article from: AIDS Weekly March 25, 2002 700+ words
...CYTR) announced that its TranzFect technology is incorporated in an experimental...that has now entered phase I clinical trials. Merck scientists hope the...the right to use CytRx's TranzFect technology in DNA-based vaccines targeted...
- CytRx's Tranzfect Technology Enters Phase I Clinical Trials As Part of Merck's...
- Press release article from: PR Newswire February 12, 2002 700+ words
...that its TranzFect technology is incorporated...entered Phase I clinical trials. Merck scientists hope the clinical trials will lead...CytRx's TranzFect technology in DNA...timeline for clinical trials, regulatory...
- Milestone payment received for TranzFect technology.
- Newspaper article from: Clinical Trials Week May 17, 2004 700+ words
...license of CytRx's TranzFect technology. CytRx's TranzFect technology is incorporated in a...Vical to use CytRx's TranzFect technology to enhance the delivery...article was prepared by Clinical Trials Week editors from staff...
- CytRx Receives Milestone Payment From Vical for TranzFect Technology.
- Press release article from: PR Newswire April 20, 2004 700+ words
...pursuant to Vical's license of CytRx's TranzFect technology. CytRx's TranzFect technology is incorporated in a plasmid DNA vaccine...agreement permits Vical to use CytRx's TranzFect technology to enhance the delivery of proteins...
- Merck & Co. Presents Preclinical Data on HIV Vaccine Program Utilizing CytRx's...
- Press release article from: PR Newswire April 2, 2001 700+ words
...CytRx the right to use CytRx's TranzFect technology in DNA-based vaccines targeted...Merck is conducting early (Phase I) clinical trials using novel vaccine technology which...affect the Company's timeline for clinical trials, regulatory approval, and, if...
- CytRx Announces First Licensing Agreement With Merck & Co., Inc. For TranzFect...
- Press release article from: PR Newswire November 6, 2000 700+ words
...with Merck & Co., Inc. (NYSE: MRK) for its TranzFect technology in DNA-based vaccines targeted against a number of infectious...which could adversely affect the Company's timeline for clinical trials, regulatory approval, and if such approval is received...
- Merck Publishes HIV Studies Utilizing CytRx's Tranzfect Technology; Results of...
- Press release article from: PR Newswire January 24, 2002 700+ words
...journal Nature on their vaccine research program against HIV which utilized CRL-1005, a component of CytRx's TranzFect technology. In November 2000 Merck licensed from CytRx the right to use TranzFect in DNA-based vaccines targeted to four...
- CytRx Receives $2 Million Initial Fee Under TranzFect License to Merck.
- Press release article from: PR Newswire December 4, 2000 700+ words
...license of CytRx's TranzFect technology. On November...rights to use its TranzFect technology in DNA-based...licenses to the TranzFect technology to treat the three...s timeline for clinical trials, regulatory approval...